Nippon Shinyaku Co., Ltd.
https://www.nippon-shinyaku.co.jp/english/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nippon Shinyaku Co., Ltd.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Two New Vaccines Join COVID Fight As China Ships Millions Overseas
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
China Sees No Variant Impact On Vaccines, Builds New mRNA Plant
Chinese officials do not expect the new strain of coronavirus emerging in the UK to impact the efficacy of inactivated virus vaccines on the cusp of conditional approval. Meanwhile, a new plant is under construction in China for domestically developed mRNA vaccines.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- NS Pharma, Inc.